EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel nucleoside analogs exhibit potent intracellular and in vivo activities against Mycobacterium avium

Ho-Sung Park iD, Do Young Kim, Ji Seok Oh, Dong Hyon Koo, Suyeon Yeom, Seungwoo Kim, Arjun Gontala, Sang-Yeop Lee, Dong Ho Kim, Kyungho Woo, Seung Il Kim, Jun Young Heo und 3 weitere

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.02160-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Ho-Sung Park und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Republic of Korea. Hauptthemen laut MEDLINE: Mycobacterium avium, Nucleosides, Anti-Bacterial Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mycobacterium avium is a major causative agent of nontuberculous mycobacterial pulmonary disease, which poses therapeutic challenges owing to its intrinsic drug resistance and the need for prolonged multidrug regimens. In this study, we identified two novel nucleoside analogs, MCCB-04-35 and MCCB-04-37, as potential therapeutic candidates against M. avium infection. Both compounds exhibited significant bacteriostatic activity in vitro and in infected macrophages, with minimal cytotoxicity. Time–kill kinetics and MIC assays confirmed their potent inhibitory effects, particularly against slow-growing mycobacteria. Checkerboard synergy testing revealed additive to synergistic interactions with clinically used antibiotics such as clarithromycin and ciprofloxacin. In a mouse model of chronic lung infection, both compounds significantly reduced pulmonary bacterial burden, inflammatory cytokine levels, and histopathological damage. Transcriptomic analysis of treated M. avium revealed the downregulation of key metabolic pathways, including oxidative phosphorylation and nitrogen metabolism, indicating disruption of intracellular energy homeostasis. These findings suggest that MCCB-04-35 and MCCB-04-37 exert antimicrobial effects through metabolic interference and may serve as effective therapeutic agents either alone or in combination for treating M. avium infections. IMPORTANCE Pulmonary disease caused by Mycobacterium avium complex (MAC) is notoriously difficult to treat due to intrinsic antibiotic resistance and the need for prolonged multidrug therapy, often poorly tolerated with suboptimal outcomes. The identification of new therapeutic candidates with novel mechanisms of action is urgently needed. Here, we report two novel nucleoside analogs, MCCB-04-35 and MCCB-04-37, exhibiting strong anti-mycobacterial activity against M. avium both in vitro and in vivo , with minimal cytotoxicity. These compounds showed additive to synergistic effects when combined with existing antibiotics such as clarithromycin. In a mouse model of chronic lung infection, they significantly reduced bacterial burden, inflammation, and tissue damage. Transcriptomic profiling revealed downregulation of metabolic pathways essential for bacterial energy production, suggesting a unique mechanism of antimicrobial action. Our findings provide promising leads for the development of more effective treatments for MAC pulmonary disease, either as monotherapy or in combination with current drugs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycobacterium aviumNucleosidesAnti-Bacterial AgentsAnimalsMiceMicrobial Sensitivity TestsMacrophagesHumansClarithromycinDrug SynergismDisease Models, AnimalFemaleCiprofloxacin

Stichwörter der Autor:innen

Mycobacterium aviumantimicrobial resistanceintracellular survivalnucleoside analogssynergistic therapy

Substanzen

NucleosidesAnti-Bacterial AgentsClarithromycinCiprofloxacin

Autor:innen und Institutionen

  • Department of Medical Science, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.
  • Department of Microbiology, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.
  • Translational Immunology Institute, School of Medicine, Chungnam National University, Daejeon, Republic of Korea.
  • System Network Inflammation Control Research Center, Chungnam National University, School of Medicine, Daejeon, Republic of Korea.
  • Department of Chemistry, Korea University, Seoul, Republic of Korea.
  • Korea Basic Science Institute (KBSI), Daejeon, Chungcheongbuk-do, Republic of Korea.

ORCID-Profile: Ho-Sung Park, Hak Joong Kim, Chul Hee Choi

Zitieren

APA

Park, H. S., Kim, D. Y., Oh, J. S., Koo, D. H., Yeom, S., Kim, S., Gontala, A., Lee, S. Y., Kim, D. H., Woo, K., Kim, S. I., Heo, J. Y., Chung, W., Kim, H. J., & Choi, C. H. (2026). Novel nucleoside analogs exhibit potent intracellular and in vivo activities against Mycobacterium avium. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02160-25

Vancouver

Park HS, Kim DY, Oh JS, Koo DH, Yeom S, Kim S, et al. Novel nucleoside analogs exhibit potent intracellular and in vivo activities against Mycobacterium avium. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02160-25

BibTeX
@article{Park2026,
  author = {Park, Ho-Sung and Kim, Do Young and Oh, Ji Seok and Koo, Dong Hyon and Yeom, Suyeon and Kim, Seungwoo and Gontala, Arjun and Lee, Sang-Yeop and Kim, Dong Ho and Woo, Kyungho and Kim, Seung Il and Heo, Jun Young and Chung, Woosuk and Kim, Hak Joong and Choi, Chul Hee},
  title = {Novel nucleoside analogs exhibit potent intracellular and in vivo activities against Mycobacterium avium},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.02160-25}
}
Kostenlos starten →